Axsome Therapeutics, Inc. (AXSM)
208.46
-1.46
(-0.70%)
USD |
NASDAQ |
Sep 03, 16:00
209.50
+1.04
(+0.50%)
After-Hours: 17:02
Axsome Therapeutics Research and Development Expense (Annual) : 182.78M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 182.78M |
| December 31, 2024 | 186.54M |
| December 31, 2023 | 97.48M |
| December 31, 2022 | 57.68M |
| December 31, 2021 | 57.98M |
| December 31, 2020 | 70.17M |
| December 31, 2019 | 53.61M |
| Date | Value |
|---|---|
| December 31, 2018 | 23.50M |
| December 31, 2017 | 19.96M |
| December 31, 2016 | 21.20M |
| December 31, 2015 | 6.777M |
| December 31, 2014 | 4.279M |
| December 31, 2013 | 1.535M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Eli Lilly & Co. | 13.34B |
| Liquidia Corp. | 38.45M |
| Filana Therapeutics, Inc. | 26.59M |
| CorMedix, Inc. | 19.33M |
| Eloxx Pharmaceuticals, Inc. | 3.056M |